<VariationArchive RecordType="classified" VariationID="11647" VariationName="NG_007264.1:g.(31343_33421)_(33522_36040)del" VariationType="Deletion" Accession="VCV000011647" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-12-11" DateCreated="2017-12-08" MostRecentSubmission="2017-12-08">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26686" VariationID="11647">
      <GeneList>
        <Gene Symbol="XIAP" FullName="X-linked inhibitor of apoptosis" GeneID="331" HGNC_ID="HGNC:592" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>Xq25</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="123859708" stop="123913972" display_start="123859708" display_stop="123913972" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="122993661" stop="123047828" display_start="122993661" display_stop="123047828" Strand="+" />
          </Location>
          <OMIM>300079</OMIM>
          <Haploinsufficiency last_evaluated="2022-07-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=XIAP">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-07-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=XIAP">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NG_007264.1:g.(31343_33421)_(33522_36040)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq25</CytogeneticLocation>
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007264.1" sequenceAccession="NG_007264" sequenceVersion="1" change="g.(31343_33421)_(33522_36040)del">
            <Expression>NG_007264.1:g.(31343_33421)_(33522_36040)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_19" sequenceAccession="LRG_19">
            <Expression>LRG_19:g.(31343_33421)_(33522_36040)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="300079.0003" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff could not provide a precise HGVS expression for allelic variant 300079.0003 because the lengths of the flanking sequences at the breakpoint (Rigaud et al., 2006, PubMed 17080092, Figure 1d) were not sufficient to define unique intronic locations. What is reported as exon 2 in the paper (second coding exon) is exon 3 in NG_007264.1.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NG_007264.1:g.(31343_33421)_(33522_36040)del AND X-linked lymphoproliferative disease due to XIAP deficiency" Accession="RCV000012413" Version="24">
        <ClassifiedConditionList TraitSetID="3179">
          <ClassifiedCondition DB="MedGen" ID="C1845076">X-linked lymphoproliferative disease due to XIAP deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2006-11-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2006-11-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-12-08" MostRecentSubmission="2017-12-08">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17080092</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3179" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2711" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Lymphoproliferative syndrome 2, X-linked</ElementValue>
                <XRef ID="X-linked+lymphoproliferative+syndrome+2/9494" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">XIAP DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="300635" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked lymphoproliferative disease due to XIAP deficiency</ElementValue>
                <XRef ID="MONDO:0010385" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XLP2</ElementValue>
                <XRef Type="MIM" ID="300635" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10916" />
                <XRef ID="10916" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes: Inappropriate immune response to Epstein-Barr virus (EBV) infection leading to hemophagocytic lymphohistiocytosis (HLH) or severe mononucleosis. Dysgammaglobulinemia. Lymphoproliferative disease (malignant lymphoma). XLP2 is most often characterized by HLH (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. HLH resulting from EBV infection is associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Dysgammaglobulinemia is typically hypogammaglobulinemia of one or more immunoglobulin subclasses. The malignant lymphomas are typically B-cell lymphomas, non-Hodgkin type, often extranodal, and in particular involving the intestine.</Attribute>
                <XRef ID="NBK1406" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301580</ID>
                <ID Source="BookShelf">NBK1406</ID>
              </Citation>
              <XRef ID="2442" DB="Orphanet" />
              <XRef ID="538934" DB="Orphanet" />
              <XRef ID="C1845076" DB="MedGen" />
              <XRef ID="MONDO:0010385" DB="MONDO" />
              <XRef Type="MIM" ID="300635" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32647" SubmissionDate="2017-12-05" DateLastUpdated="2017-12-08" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300079.0003_LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2" title="XIAP, 2606-BP DEL_LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2" />
        <ClinVarAccession Accession="SCV000032647" DateUpdated="2017-12-08" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2006-11-02">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected males from a family (family 2) with X-linked lymphoproliferative syndrome (XLP2; 300635), Rigaud et al. (2006) detected a hemizygous deletion of 2,606 nucleotides encompassing exon 2 of the XIAP gene.</Attribute>
              <Citation>
                <ID Source="PubMed">17080092</ID>
              </Citation>
              <XRef DB="OMIM" ID="300635" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="XIAP" />
          </GeneList>
          <Name>XIAP, 2606-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2606-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300079.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="32647" TraitType="Disease" MappingType="Name" MappingValue="LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2" MappingRef="Preferred">
        <MedGen CUI="C1845076" Name="X-linked lymphoproliferative disease due to XIAP deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

